An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Nanatinostat/valganciclovir combination therapy (Primary) ; Pembrolizumab (Primary) ; Valganciclovir (Primary)
- Indications Carcinoma; Gastric cancer; Leiomyosarcoma; Nasopharyngeal cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Viracta Therapeutics
- 07 Mar 2024 According to a Viracta Therapeutics media release, the company expects to determine the recommended Phase 2 dose (RP2D) in the second half of 2024, Initiate a dose-optimization cohort to confirm the RP2D as part of the studys Phase 2 expansion by year-end 2024.
- 07 Mar 2024 According to a Viracta Therapeutics media release, the company completed enrollment into first split daily dosing cohort of the Phase 1b/2 study of Nana-val in patients with advanced EBV+ solid tumors
- 29 Feb 2024 According to a Viracta Therapeutics media release, the company look forward to publish data from the Phase 1b/2 clinical trial and reporting topline PTCL cohort data from Stage 1 of the NAVAL-1 trial in the second quarter of 2024.